Randomized controlled study of the efficacy of pancreatic enzyme replacement therapy with pancrelipase for pancreatic exocrine insufficiency in patients with unresectable pancreatic cancer.

Randomized controlled study of the efficacy of pancreatic enzyme replacement therapy with pancrelipase for pancreatic exocrine insufficiency in patients with unresectable pancreatic cancer. - Randomized controlled study of the efficacy of pancreatic enzyme replacement therapy with pancrelipase for pancreatic exocrine insufficiency in patients with unresectable pancreatic cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009912

Enrollment

Registered

2013-01-31

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Oral administration of pancrelipase (1800mg/day for 3 months) Oral administration of pancreatin (3000mg/day for 3 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with cytologically or histologically proven, unresectable adenocarcinoma of the pancreas (2)Age >= 20 years (3)ECOG Performance status of 0-1 (4)Written informed consent (5)Estimated prognosis >= 3 months (6)adequate oral intake (7)adequate organ function

Exclusion criteria

Exclusion criteria: (1)Gastrointestinal obstruction (2)Severe concurrent disease (3)Pregnant or lactating women (4)Hypersensitivity to porcine or bovine protein, or severe drug hypersensitibity (5)History of gastrointestinal tract surgery (6)Prior chemotherapy or radiotherapy (7)Mental disorder (8)Inadequate physical condition

Design outcomes

Primary

Measure	Time frame
The change in body weight from baseline to 3 months	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026